MYD88 and diffuse large B-cell lymphoma: For example, a previous clinical trial on ibrutinib reported an ORR of 37% in activated B-cell-like DLBCL subjects, among which the ORR was higher in patients with B-cell receptor pathway mutations (55.5%) and even higher in patients with MYD88 mutations (80%)8.